| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10911416 | Lung Cancer | 2011 | 6 Pages |
Abstract
The outcome for second-line therapy for SCLC was poor and benefit appeared to be limited to those patients with good PS and rechallenged with platinum-based chemotherapy. Platinum-based rechallenge should be considered as a standard comparator in future randomized controlled trials of SL chemotherapy.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Marina Chiara Garassino, Valter Torri, Giovanni Michetti, Monica Lo Dico, Nicla La Verde, Stefania Aglione, Andrea Mancuso, Elisa Gallerani, Domenico Galetta, Olga Martelli, Elena Collovà , Sonia Fatigoni, Antonio Ghidini, Chiara Saggia, Claudia Bareggi,